AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BTIG Reiterates Buy Rating on Lucid Diagnostics with $2.00 Price Target
ByAinvest
Wednesday, Aug 20, 2025 6:59 pm ET1min read
Lucid Diagnostics (LUCD) has received a Buy rating and $2.00 price target from BTIG analyst Mark Massaro. The company's shares closed at $0.99. The analyst consensus on Lucid Diagnostics is a Strong Buy with an average price target of $3.25, a 227.06% upside from current levels. Corporate insider sentiment is positive, with 7 insiders buying shares over the past quarter.
Lucid Diagnostics Inc. (LUCD), a commercial-stage cancer prevention medical diagnostics company, has received a positive analyst rating from BTIG analyst Mark Massaro. The analyst has assigned a Buy rating to the company's shares, with a $2.00 price target. This rating aligns with the strong Buy consensus among analysts, who have an average price target of $3.25, representing a 227.06% upside from the current share price of $0.99 [2].The positive analyst sentiment is backed by corporate insider activity, with seven insiders buying shares over the past quarter. This indicates a positive outlook among insiders, who are typically well-informed about the company's prospects.
Lucid Diagnostics has been making significant strides in its business operations and financial performance. In the second quarter of 2025, the company processed 2,756 EsoGuard® tests, recognized revenue of $1.2 million, and ended the quarter with over $30 million in proforma cash. The company is also extending its runway well past upcoming reimbursement milestones [1].
Additionally, Lucid Diagnostics is set to participate in an upcoming Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting on Medicare Local Coverage Determination (LCD) for its EsoGuard product. The meeting, scheduled for September 4, 2025, is a significant milestone that could lead to positive Medicare coverage for the product [1].
The company's stock has been performing well, with shares closing at $0.99. The positive analyst rating and insider buying activity suggest that investors may find Lucid Diagnostics an attractive investment opportunity.
References:
[1] https://stockanalysis.com/stocks/lucd/
[2] https://www.biospace.com/press-releases/lucid-diagnostics-provides-business-update-and-reports-second-quarter-2025-financial-results
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet